Skripsi
MOLECULAR DOCKING SENYAWA BIOAKTIF EMODIN TERHADAP RESEPTOR VEGF PADA KANKER SERVIKS
Cervical cancer is the main cause of cancer death among woman and the third most cancer case in the world. High expression of VEGF in cervical cancer is linked to a poor prognosis, therefore anti-VEGF therapy has an important role in cervical cancer resolution. Several studies show that emodin inhibit proliferation, migration, and a formation of endothelial cells stimulated by VEGF. This research aims to discover the interaction of the bioactive compound emodin with VEGF receptor in cervical cancer with in silico using molecular docking. Molecular docking involves several steps, starting with the preparation of the bioactive compound structure, preparation of the target protein structure, validation of the molecular docking method, and docking of the bioactive compound to the target protein. A lower binding energy value between the bioactive compound and the target protein indicates that the formed bond is stronger and more stable. The docking results showed the binding energy from VEGFR2-emodin complex is -7.78 kcal/mol with three hydrogen bonds formed with GLU915, CYS917, LEU838 amino acids and three van der Waals formed with PHE916, GLY920, VAL 846 amino acids. There is an interaction between the bioactive compound, emodin and VEGFR2, characterized by a good binding value (-7,78 kkal/mol) and formed a stable binding characterized by 3 hydrogen bonds and 3 van der Waals interactions.
| Inventory Code | Barcode | Call Number | Location | Status |
|---|---|---|---|---|
| 2407006722 | T160705 | T1607052024 | Central Library (REFERENCE) | Available but not for loan - Not for Loan |
No other version available